Invitation to the Annual General Meeting of Cereno Scientific AB (publ)

Shareholders of Cereno Scientific AB (publ), 556890-4071 are hereby invited to the Annual General Meeting to be held on Wednesday, June 21, 2017, at 12 noon at Gula Salongen in the University of Gothenburg (main building), Universitetsplatsen 1, Vasaparken, in Gothenburg, Sweden.

For further information, including requirements, please see the full invitation invitation in Swedish on www.cerenoscientific.se or www.aktietorget.se


For more information about Cereno Scientific, please contact:
Sten R Sörensen, CEO

Tel. +46 733 74 03 74
E-mail: sten.sorensen@cerenoscientific.com


About Cereno Scientific AB
Cereno Scientific develops preventive medicines to treat thrombosis-related disease, such as myocardial infarction and stroke. These novel therapeutics stimulate the body's own intelligent clot-busting system, and are being developed to treat thrombosis-related cardiovascular diseases on the global market. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn leads to a high risk of new blood clots. The benefit with Cereno Scientific's drug candidate, CS1, is an improved balance between preventing blood clots and treatment-related side effects - leading to more effective treatment. CS1 is a re-formulation of a known compound and, as such, is expected to have a relatively short development time. It is based on many years of research and its effectiveness on risk factors is documented in experimental studies and early clinical studies. Preventive effectiveness against blood clots has been demonstrated in animal in vivo studies. Indication of clinical preventive effectiveness against heart attacks has been demonstrated in two large epidemiological studies. CS1 has a unique mechanism of action, a potentially wide range of indication opportunities connected to large blood clot-related diseases and, consequently, a large market potential. The Göteborg-based company is listed on the AktieTorget stock market, conducts research activities at AstraZeneca's BioVentureHub in Göteborg and is supported by GU Ventures. For more information, see www.cerenoscientific.se.

Tags:

Subscribe

Documents & Links